Soleus Capital

All recorded activity

By stage

Series C+2

Series B1

Undisclosed1

Biotech3

Healthtech1

United States4

4 in all activity

Aug 18

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries D

Role not disclosed

Aug 12

Makes organ preservation and perfusion technology for liver transplants

$110MSeries C+Debt

Role not disclosed

Jul 22

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed